RTA 408 Capsules in Patients With Mitochondrial Myopathy - MOTOR

PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

May 5, 2015

Primary Completion Date

November 2, 2017

Study Completion Date

November 30, 2017

Conditions
MItochondrial Myopathies
Interventions
DRUG

Omaveloxolone capsules, 2.5 mg

DRUG

omaveloxolone capsules, 5 mg

DRUG

omaveloxolone capsules, 10 mg

DRUG

Placebo capsules

DRUG

omaveloxolone capsules, 20 mg

DRUG

omaveloxolone capsules, 40 mg

DRUG

omaveloxolone capsules, 80 mg

DRUG

omaveloxolone capsules, 160 mg

Trial Locations (9)

15224

University of Pittsburgh, Pittsburgh

19104

The Children's Hospital of Philadelphia, Philadelphia

44308

Akron Children's Hospital, Akron

75231

Insitute for Exercise & Environmental Medicine, Dallas

77030

Baylor College of Medicine, Houston

University of Texas Medical School at Houston, Houston

90095

UCLA, Los Angeles

02114

Mass General Hospital, Boston

DK-2100

Neuromuscular Clinic, Rigshospitalet, University of Copenhagen, Copenhagen

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Biogen

INDUSTRY